Viatris addresses Elidel supply disruptions in Russia amid lack of direct substitutes

Elidel supplies disrupted in Russia

Russia is facing disruptions in supplies of Elidel, a German-made medicine used for atopic dermatitis, according to RBC. Viatris, the manufacturer identified in the report, has addressed the interruption and said it expects to resolve the availability problem. The source material does not specify how many packs are unavailable, which regions are most affected or when normal deliveries will resume.

The shortage is significant because Elidel has no direct substitute on the Russian market, RBC reported. That limits the ability of pharmacies, distributors and patients to switch immediately to an equivalent product when stocks run low. It also makes the timing and consistency of renewed deliveries more important than they would be in a market with several interchangeable medicines.

Children form a large affected group

Atopic dermatitis affects about 20% of children, according to the information cited by RBC. The figure indicates a potentially broad patient population, although it does not show how many patients in Russia currently use Elidel or how many prescriptions may be affected by the disruption. No figures on adult prevalence, sales volumes or the medicine’s share of the Russian dermatitis-treatment market were provided.

For pharmacies, the absence of a direct analogue can translate into unanswered demand rather than a simple transfer of sales to another brand. Wholesalers may also face uneven inventories if remaining packs are concentrated in particular regions or pharmacy chains. The supplied report does not provide regional stock data, so the geographic scale of the shortage cannot be quantified.

Restoration timetable remains unclear

Viatris has promised to address the supply situation, but the available source text does not give a firm restoration date or describe the cause of the interruption. It also does not say whether the constraint arose in production, international logistics, regulatory procedures or domestic distribution. Without those details, market participants cannot determine whether the shortage is a temporary delivery gap or a problem that could persist across several supply cycles.

The case highlights the operational risk created when an imported medicine without a direct local substitute becomes difficult to obtain. Producers and distributors will be watching for concrete information on shipment volumes and delivery dates, while pharmacies need visibility on where available stocks are located. For patients and medical professionals, the central issue is continuity of access. Until Viatris provides a specific timetable and supplies return to the market, the shortage will remain sensitive because of the medicine’s distinct position and the scale of atopic dermatitis among children.